Details of the Drug

General Information of Drug (ID: DM5QWEL)

• Drug Name: Guanabenz
• Synonyms: GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine

Indication

Disease Entry	ICD 11	Status	REF
High blood pressure	BA00	Approved	[1], [2]

• Therapeutic Class: Sympatholytics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 231.08
  Topological Polar Surface Area (xlogp); 1.7
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption: The absorption of drug is approximately 50% from gastrointestinal tract [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 hours [4]
  Metabolism: The drug is metabolized via the hepatic [3]
• Chemical Identifiers:
  Formula: C8H8Cl2N4
  IUPAC Name: 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
  Canonical SMILES: C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
  InChI: InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
  InChIKey: WDZVGELJXXEGPV-YIXHJXPBSA-N
• Cross-matching ID:
  PubChem CID: 5702063
  ChEBI ID: CHEBI:5553
  CAS Number: 60329-03-5
  DrugBank ID: DB00629
  TTD ID: D0L4HY
  VARIDT ID: DR01410
  INTEDE ID: DR0794

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Guanabenz (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Guanabenz and Cariprazine.	Bipolar disorder [6A60]	[34]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Guanabenz and Isocarboxazid.	Depression [6A70-6A7Z]	[35]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Guanabenz and Tranylcypromine.	Depression [6A70-6A7Z]	[36]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Guanabenz and OPC-34712.	Depression [6A70-6A7Z]	[34]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Guanabenz and Phenelzine.	Depression [6A70-6A7Z]	[35]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Guanabenz and Procarbazine.	Hodgkin lymphoma [2B30]	[35]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Guanabenz and Propiomazine.	Insomnia [7A00-7A0Z]	[37]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Guanabenz and ITI-007.	Insomnia [7A00-7A0Z]	[34]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Guanabenz and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[38]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Guanabenz and Lasmiditan.	Migraine [8A80]	[39]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Guanabenz and Ozanimod.	Multiple sclerosis [8A40]	[35]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Guanabenz and Promethazine.	Nausea/vomiting [MD90]	[34]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Guanabenz and Rasagiline.	Parkinsonism [8A00]	[35]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Guanabenz and Levomepromazine.	Psychotic disorder [6A20-6A25]	[37]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Guanabenz and Quetiapine.	Schizophrenia [6A20]	[34]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Guanabenz and Mesoridazine.	Schizophrenia [6A20]	[37]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Guanabenz and Thioridazine.	Schizophrenia [6A20]	[37]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Guanabenz and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Guanabenz and Iloperidone.	Schizophrenia [6A20]	[34]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Guanabenz and Paliperidone.	Schizophrenia [6A20]	[34]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Guanabenz and Perphenazine.	Schizophrenia [6A20]	[34]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Guanabenz and Molindone.	Schizophrenia [6A20]	[34]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Guanabenz and Thiothixene.	Schizophrenia [6A20]	[34]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Guanabenz and Trifluoperazine.	Schizophrenia [6A20]	[34]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Guanabenz and Risperidone.	Schizophrenia [6A20]	[34]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Guanabenz and Amisulpride.	Schizophrenia [6A20]	[34]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Guanabenz and Asenapine.	Schizophrenia [6A20]	[34]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Guanabenz and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[37]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Guanabenz and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[37]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5443).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074149.
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [6] A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
• [7] Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
• [8] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [9] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [10] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [11] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [12] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [13] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [14] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [15] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [16] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [17] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [18] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [19] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [20] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [21] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [22] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [23] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [24] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [25] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [26] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [27] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [28] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [29] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [30] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [31] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [32] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [33] Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
• [34] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [35] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [36] Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
• [37] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [38] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [39] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.